Short Interest in Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Decreases By 74.3%

Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) was the target of a significant decline in short interest during the month of January. As of January 15th, there was short interest totalling 117,500 shares, a decline of 74.3% from the December 31st total of 457,500 shares. Currently, 0.8% of the shares of the company are sold short. Based on an average daily trading volume, of 3,580,000 shares, the days-to-cover ratio is currently 0.0 days.

Virpax Pharmaceuticals Price Performance

Virpax Pharmaceuticals stock traded down $0.01 during mid-day trading on Thursday, reaching $0.31. The company had a trading volume of 510,607 shares, compared to its average volume of 520,959. The company has a 50 day moving average of $0.37 and a 200-day moving average of $0.68. Virpax Pharmaceuticals has a 52 week low of $0.23 and a 52 week high of $5.48.

Hedge Funds Weigh In On Virpax Pharmaceuticals

An institutional investor recently bought a new position in Virpax Pharmaceuticals stock. Garden State Investment Advisory Services LLC acquired a new stake in shares of Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 57,300 shares of the company’s stock, valued at approximately $40,000. Garden State Investment Advisory Services LLC owned 1.17% of Virpax Pharmaceuticals at the end of the most recent quarter. Institutional investors and hedge funds own 32.23% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Maxim Group reiterated a “hold” rating on shares of Virpax Pharmaceuticals in a report on Wednesday, October 9th.

About Virpax Pharmaceuticals

Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.